Please assess the completion status of the following clinical trial:

Trial Title: NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: ≥ 10 years old and ≤ 75 years old, male or female;~2. Meet the diagnostic criteria for recurrent AML: detection of leukemia cells after complete remission (CR) or \>0.1% of leukemia cells in bone marrow, including recurrence after allogeneic hematopoietic stem cell transplantation, or extramedullary infiltration of leukemia cells;~3. Initial cases with failure of 2 lines of standard treatment; patients who relapsed within 12 months after consolidation intensification after CR; recurrence in 12 months and no respond to conventional chemotherapy; 2 or more recurrences; persistent extramedullarial leukemia;~4. Patients currently have no effective treatment options, such as chemotherapy or allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to infuse NKG2D CAR-NK cells as the first treatment option;~5. Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points;~6. Estimated survival \> 3 months~7. Flow cytometry check for NKG2D ligand expression on the surface of cancer cells for a reference of selecting patients~8. The main organs of the patient are well functioned: (1) cardiac function: no heart disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver function: TBIL≦3ULN, AST≦2.5ULN, ALT≦2.5ULN; (3) Renal function: Cr≦1.25ULN;~9. The patient's peripheral superficial vein can meet the needs of intravenous injection;~10. No other serious diseases that conflict with this protocol (e.g., autoimmune diseases, immunodeficiency, organ transplantation);~11. No history of other malignant tumors;~12. Women of childbearing age must be tested negative for pregnancy within 7 days, and subjects of childbearing age must use appropriate contraception during both the trial and for 3 months after the test;~13. Subjects have negative HIV, HBV, HCV, syphilis serology test results~14. Written informed consent form must be signed before enrollment.~Exclusion Criteria:~1. Acute promyelocytic leukemia (type M3);~2. Patients with cardiac insufficiency, patients with hepatic and renal insufficiency;~3. Those who need treatment with other malignant tumors;~4. Poorly controlled hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>90 mmHg) or clinically significant cardiovascular and cerebrovascular diseases such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on research treatment;~5. Also suffering from other hematologic diseases (such as hemophilia, myelofibrosis, etc., which researchers consider unsuitable for inductees);~6. Diffuse vascular internal coagulation;~7. Concomitant serious infection or other serious underlying medical condition;~8. Have immunodeficiency and autoimmune diseases;~9. Have severe allergic diseases;~10. Clinical symptoms of brain dysfunction or severe mental illness that can not understand or follow the research protocol;~11. Have participated in clinical trials of other drugs within 4 weeks or within 21 days of surgery;~12. Have received cell therapy in the previous 1 month;~13. Have received hormonal drug therapy in the previous 14 days;~14. Known HIV-positive patients or hepatitis B and C patients and syphilis patients;~15. Have received organ transplants (excluding stem cell transplant patients);~16. Drug abuse, medical, psychological or social conditions that may interfere with a subject's participation in the study or evaluation of the results of the study;~17. Pregnant or lactating women;~18. Those who cannot be followed up as scheduled;~19. Investigator considers that the subject has any clinical or laboratory abnormalities or compliance problems and is not suitable to participate in this clinical study.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NKG2DL-specific CAR-NK cells (Type: EXPERIMENTAL): Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy